SCM
RIGL icon

Soleus Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Soleus Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72.1M Buy
1,843,504
+1,833,504
+18,335% +$56.6M 2.49% 8
2026
Q1 		$270K Sell
10,000
-290,034
-97% -$9.75M 0.01% 89
2025
Q4 		$12.9M Sell
300,034
-29,976
-9% -$1.13M 0.47% 46
2025
Q3 		$9.35M Sell
330,010
-328,135
-50% -$9.82M 0.47% 48
2025
Q2 		$12.3M Sell
658,145
-472,534
-42% -$8.96M 0.82% 35
2025
Q1 		$20.3M Hold
1,130,679
– – 1.46% 22
2024
Q4 		$19M Buy
1,130,679
+195,891
+21% +$3.76M 1.2% 25
2024
Q3 		$15.1M Sell
934,788
-108,909
-10% -$1.28M 1.17% 32
2024
Q2 		$8.58M Buy
1,043,697
+119,498
+13% +$1.25M 0.76% 43
2024
Q1 		$13.7M Sell
924,199
-20,059
-2% -$270K 1.02% 32
2023
Q4 		$13.7M Sell
944,258
-536,044
-36% -$5.48M 1.52% 21
2023
Q3 		$16M Buy
1,480,302
+62,500
+4% +$752K 1.48% 24
2023
Q2 		$18.3M Buy
1,417,802
+137,500
+11% +$1.86M 2.03% 14
2023
Q1 		$16.9M Buy
+1,280,302
New +$20.3M 1.75% 15

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Soleus Capital Management's RIGL Position: Q2 2026 in Review

Soleus Capital Management increased its Rigel Pharmaceuticals (RIGL) stake by 18,335% in Q2 2026, buying an estimated $56.6M and bringing the position to 1,843,504 shares worth $72.1M. The position accounts for 2.49% of the portfolio, ranked #8.

Soleus Capital Management first reported a position in RIGL in Q1 2023 and has held it in 14 quarters since. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Soleus Capital Management held 1,843,504 shares of Rigel Pharmaceuticals worth $72.1M as of Q2 2026.
  • Soleus Capital Management bought 1,833,504 Rigel Pharmaceuticals shares in Q2 2026, an estimated $56.6M.
  • Rigel Pharmaceuticals made up 2.49% of Soleus Capital Management's portfolio in Q2 2026, its #8 holding.
  • Soleus Capital Management first reported a position in Rigel Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.